Hidehito Kotani

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs <i>In vitro</i> and <i>In vivo</i>

Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru et al. · Molecular Cancer Therapeutics · 2010 · 938 citations · Full text

Medicine, Oncology, Pharmacology +17

Role of the Toll-like Receptor 4/NF-κB Pathway in Saturated Fatty Acid–Induced Inflammatory Changes in the Interaction Between Adipocytes and Macrophages

Takayoshi Suganami, Kanami Tanimoto-Koyama, Junko Nishida et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2006 · 804 citations · Full text

Life Sciences, Biochemistry, Immunology +17

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Hiroshi Hirai, Yoshikazu Iwasawa, Megumu Okada et al. · Molecular Cancer Therapeutics · 2009 · 550 citations

Life Sciences, Molecular Biology, Pharmacology +17

Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-positive Monocytes in Mice

Kazuhiko Takahashi, Shinji Mizuarai, Hiromitsu Araki et al. · Journal of Biological Chemistry · 2003 · 326 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

Shinji Mizuarai, Naohiko Aozasa, Hidehito Kotani · International Journal of Cancer · 2003 · 317 citations

Medicine, Oncology, Pharmacology +17